Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies.
By S. Schwartz, C. Regillo, B. Lam, D. Eliott, P. Rosenfeld, N. Gregori, J. Hubschman, Janet L. Davis, Gad Heilwell, M. Spirn and 9 more. The Lancet, 2015
1,187 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/5e32afaf6cad1251fc806db009d43d1c6e4460ce
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. L. Ginn
- A. Amaya
- I. Alexander
- Michael Edelstein
- M. Abedi
- A. Trounson
- Courtney A. McDonald
Citations in the corpus
- Gene therapy clinical trials worldwide to 2017: An update (2018, background): “Although important issues still require resolution, clinical trials using stem cells to target retinal degeneration, heart failure, diabetes and spinal cord injury are underway.(152-155) Most of these trials have used cells differentiated from human pluripotent stem cells; however, one trial using i”
- Stem Cell Therapies in Clinical Trials: Progress and Challenges. (2015, background): “group have used human fetalderived neural stem progenitors, which show lifelong lysosomal enzyme production, to treat very advanced infantile or late-infantile ceroid lipofuscinosis (Batten’s disease) in children without any detectable adverse events (Selden et al., 2013).”